Human papillomavirus vaccination in commercially-insured vaccine-eligible males and females, United States, 2007–2014
In the United States, the Advisory Committee on Immunization Practices (ACIP) has recommended routine human papillomavirus (HPV) vaccination at age 11–12 years since 2006 for girls and since 2011 for boys. ACIP also recommends vaccination through age 26 for females and through age 21 for males; male...
Gespeichert in:
Veröffentlicht in: | Vaccine 2018-05, Vol.36 (23), p.3381-3386 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3386 |
---|---|
container_issue | 23 |
container_start_page | 3381 |
container_title | Vaccine |
container_volume | 36 |
creator | Gargano, Julia W. Zhou, Fangjun Stokley, Shannon Markowitz, Lauri E. |
description | In the United States, the Advisory Committee on Immunization Practices (ACIP) has recommended routine human papillomavirus (HPV) vaccination at age 11–12 years since 2006 for girls and since 2011 for boys. ACIP also recommends vaccination through age 26 for females and through age 21 for males; males may be vaccinated through age 26. We describe vaccine uptake in adolescents and young adults using data from MarketScan Commercial Claims and Encounters.
We analyzed data on persons aged 11–26 years on December 31, 2014 who were continuously enrolled in a MarketScan health plan from age 11 through year 2014, or from 2006 to 2014 if aged ≥11 years in 2006 (916,513 females, 951,082 males). Individuals were grouped based on their age (years) in 2014: 11–12 (born 2002–03), 13–14 (2000–01), 15–16 (1998–99), 17–18 (1996–97), 19–21 (1993–95), and 22–26 (1988–1992). We calculated cumulative coverage with ≥1 HPV vaccine dose by sex, birth cohort, and calendar year.
In females, the proportion initiating vaccination at age 11–12 years was low in 2008 and 2010 (12.6% and 11.1%) and higher in 2012 (15.7%) and 2014 (19.5%); in males, initiation at age 11–12 was 0.9% in 2010, 8.3% in 2012, and 15.1% in 2014. In females who aged into vaccine eligibility, cumulative coverage by 2014 was higher in older cohorts (17–18: 53%; 15–16: 47%; 13–14: 39%; 11–12: 19.5%). For males, cumulative coverage by 2014 was similar in those aged 13–14, 15–16, and 17–18 years (28.9%, 32.5%, 30.3%), and lower in those aged 11–12 (15.1%), 19–21 (18.4%), and 22–26 years (4.5%).
The proportion of males and females initiating vaccination at the recommended ages was low. Although more females than males were vaccinated in all cohorts, the male–female differences were smaller in younger than older cohorts. The trajectory of male vaccination uptake could signal higher acceptability in males. |
doi_str_mv | 10.1016/j.vaccine.2018.03.045 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2036201458</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X18303906</els_id><sourcerecordid>2039813012</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-e9506b58e106e23751670190d99f0abb221227d60678dffdadc2877c474dfb413</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhi1ERbeFRwBF4sKhCWM7jpMTqqqWIlXiAJW4WY49QV45zmIni3rjHXhDnqQOu3DgwmlmpG_--TU_IS8pVBRo83Zb7bUxLmDFgLYV8Apq8YRsaCt5yQRtn5INsKYuawpfTslZSlsAEJx2z8gp6yQXnNEN-X67jDoUO71z3k-j3ru4pOIgrWc3hcKFwkzjiNE47f1D6UJaItojgyV699X1HotRe0yFDrYY8Hd_UdwHN2f006zndWQA8tePn9lw_ZycDNonfHGs5-T-5vrz1W159_H9h6vLu9Lwjs8ldgKaXrRIoUHGpaCNBNqB7boBdN8zRhmTtoFGtnYYrLaGtVKaWtZ26GvKz8mbg-4uTt8WTLMaXTLovQ44LUkx4M3qR7QZff0Pup2WGLK7lepayoGyTIkDZeKUUsRB7aIbdXxQFNSajNqq42vUmowCrnIyee_VUX3pR7R_t_5EkYF3BwDzO_YOo0rGYTBoXUQzKzu5_5x4BKj2oaE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2039813012</pqid></control><display><type>article</type><title>Human papillomavirus vaccination in commercially-insured vaccine-eligible males and females, United States, 2007–2014</title><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Gargano, Julia W. ; Zhou, Fangjun ; Stokley, Shannon ; Markowitz, Lauri E.</creator><creatorcontrib>Gargano, Julia W. ; Zhou, Fangjun ; Stokley, Shannon ; Markowitz, Lauri E.</creatorcontrib><description>In the United States, the Advisory Committee on Immunization Practices (ACIP) has recommended routine human papillomavirus (HPV) vaccination at age 11–12 years since 2006 for girls and since 2011 for boys. ACIP also recommends vaccination through age 26 for females and through age 21 for males; males may be vaccinated through age 26. We describe vaccine uptake in adolescents and young adults using data from MarketScan Commercial Claims and Encounters.
We analyzed data on persons aged 11–26 years on December 31, 2014 who were continuously enrolled in a MarketScan health plan from age 11 through year 2014, or from 2006 to 2014 if aged ≥11 years in 2006 (916,513 females, 951,082 males). Individuals were grouped based on their age (years) in 2014: 11–12 (born 2002–03), 13–14 (2000–01), 15–16 (1998–99), 17–18 (1996–97), 19–21 (1993–95), and 22–26 (1988–1992). We calculated cumulative coverage with ≥1 HPV vaccine dose by sex, birth cohort, and calendar year.
In females, the proportion initiating vaccination at age 11–12 years was low in 2008 and 2010 (12.6% and 11.1%) and higher in 2012 (15.7%) and 2014 (19.5%); in males, initiation at age 11–12 was 0.9% in 2010, 8.3% in 2012, and 15.1% in 2014. In females who aged into vaccine eligibility, cumulative coverage by 2014 was higher in older cohorts (17–18: 53%; 15–16: 47%; 13–14: 39%; 11–12: 19.5%). For males, cumulative coverage by 2014 was similar in those aged 13–14, 15–16, and 17–18 years (28.9%, 32.5%, 30.3%), and lower in those aged 11–12 (15.1%), 19–21 (18.4%), and 22–26 years (4.5%).
The proportion of males and females initiating vaccination at the recommended ages was low. Although more females than males were vaccinated in all cohorts, the male–female differences were smaller in younger than older cohorts. The trajectory of male vaccination uptake could signal higher acceptability in males.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2018.03.045</identifier><identifier>PMID: 29735321</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adolescents ; Adults ; Age ; Data processing ; Enrollments ; Epidemiology ; Females ; Girls ; Human papillomavirus ; Immunization ; Insurance claims ; Insurance claims data ; Insurance coverage ; Males ; Sex differences ; Teenagers ; Vaccination ; Vaccination policy ; Vaccine ; Vaccines ; Young adults</subject><ispartof>Vaccine, 2018-05, Vol.36 (23), p.3381-3386</ispartof><rights>2018</rights><rights>Published by Elsevier Ltd.</rights><rights>Copyright Elsevier Limited May 31, 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-e9506b58e106e23751670190d99f0abb221227d60678dffdadc2877c474dfb413</citedby><cites>FETCH-LOGICAL-c393t-e9506b58e106e23751670190d99f0abb221227d60678dffdadc2877c474dfb413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2039813012?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,46002,64392,64394,64396,72476</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29735321$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gargano, Julia W.</creatorcontrib><creatorcontrib>Zhou, Fangjun</creatorcontrib><creatorcontrib>Stokley, Shannon</creatorcontrib><creatorcontrib>Markowitz, Lauri E.</creatorcontrib><title>Human papillomavirus vaccination in commercially-insured vaccine-eligible males and females, United States, 2007–2014</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>In the United States, the Advisory Committee on Immunization Practices (ACIP) has recommended routine human papillomavirus (HPV) vaccination at age 11–12 years since 2006 for girls and since 2011 for boys. ACIP also recommends vaccination through age 26 for females and through age 21 for males; males may be vaccinated through age 26. We describe vaccine uptake in adolescents and young adults using data from MarketScan Commercial Claims and Encounters.
We analyzed data on persons aged 11–26 years on December 31, 2014 who were continuously enrolled in a MarketScan health plan from age 11 through year 2014, or from 2006 to 2014 if aged ≥11 years in 2006 (916,513 females, 951,082 males). Individuals were grouped based on their age (years) in 2014: 11–12 (born 2002–03), 13–14 (2000–01), 15–16 (1998–99), 17–18 (1996–97), 19–21 (1993–95), and 22–26 (1988–1992). We calculated cumulative coverage with ≥1 HPV vaccine dose by sex, birth cohort, and calendar year.
In females, the proportion initiating vaccination at age 11–12 years was low in 2008 and 2010 (12.6% and 11.1%) and higher in 2012 (15.7%) and 2014 (19.5%); in males, initiation at age 11–12 was 0.9% in 2010, 8.3% in 2012, and 15.1% in 2014. In females who aged into vaccine eligibility, cumulative coverage by 2014 was higher in older cohorts (17–18: 53%; 15–16: 47%; 13–14: 39%; 11–12: 19.5%). For males, cumulative coverage by 2014 was similar in those aged 13–14, 15–16, and 17–18 years (28.9%, 32.5%, 30.3%), and lower in those aged 11–12 (15.1%), 19–21 (18.4%), and 22–26 years (4.5%).
The proportion of males and females initiating vaccination at the recommended ages was low. Although more females than males were vaccinated in all cohorts, the male–female differences were smaller in younger than older cohorts. The trajectory of male vaccination uptake could signal higher acceptability in males.</description><subject>Adolescents</subject><subject>Adults</subject><subject>Age</subject><subject>Data processing</subject><subject>Enrollments</subject><subject>Epidemiology</subject><subject>Females</subject><subject>Girls</subject><subject>Human papillomavirus</subject><subject>Immunization</subject><subject>Insurance claims</subject><subject>Insurance claims data</subject><subject>Insurance coverage</subject><subject>Males</subject><subject>Sex differences</subject><subject>Teenagers</subject><subject>Vaccination</subject><subject>Vaccination policy</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Young adults</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkcFu1DAQhi1ERbeFRwBF4sKhCWM7jpMTqqqWIlXiAJW4WY49QV45zmIni3rjHXhDnqQOu3DgwmlmpG_--TU_IS8pVBRo83Zb7bUxLmDFgLYV8Apq8YRsaCt5yQRtn5INsKYuawpfTslZSlsAEJx2z8gp6yQXnNEN-X67jDoUO71z3k-j3ru4pOIgrWc3hcKFwkzjiNE47f1D6UJaItojgyV699X1HotRe0yFDrYY8Hd_UdwHN2f006zndWQA8tePn9lw_ZycDNonfHGs5-T-5vrz1W159_H9h6vLu9Lwjs8ldgKaXrRIoUHGpaCNBNqB7boBdN8zRhmTtoFGtnYYrLaGtVKaWtZ26GvKz8mbg-4uTt8WTLMaXTLovQ44LUkx4M3qR7QZff0Pup2WGLK7lepayoGyTIkDZeKUUsRB7aIbdXxQFNSajNqq42vUmowCrnIyee_VUX3pR7R_t_5EkYF3BwDzO_YOo0rGYTBoXUQzKzu5_5x4BKj2oaE</recordid><startdate>20180531</startdate><enddate>20180531</enddate><creator>Gargano, Julia W.</creator><creator>Zhou, Fangjun</creator><creator>Stokley, Shannon</creator><creator>Markowitz, Lauri E.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20180531</creationdate><title>Human papillomavirus vaccination in commercially-insured vaccine-eligible males and females, United States, 2007–2014</title><author>Gargano, Julia W. ; Zhou, Fangjun ; Stokley, Shannon ; Markowitz, Lauri E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-e9506b58e106e23751670190d99f0abb221227d60678dffdadc2877c474dfb413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adolescents</topic><topic>Adults</topic><topic>Age</topic><topic>Data processing</topic><topic>Enrollments</topic><topic>Epidemiology</topic><topic>Females</topic><topic>Girls</topic><topic>Human papillomavirus</topic><topic>Immunization</topic><topic>Insurance claims</topic><topic>Insurance claims data</topic><topic>Insurance coverage</topic><topic>Males</topic><topic>Sex differences</topic><topic>Teenagers</topic><topic>Vaccination</topic><topic>Vaccination policy</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Young adults</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gargano, Julia W.</creatorcontrib><creatorcontrib>Zhou, Fangjun</creatorcontrib><creatorcontrib>Stokley, Shannon</creatorcontrib><creatorcontrib>Markowitz, Lauri E.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gargano, Julia W.</au><au>Zhou, Fangjun</au><au>Stokley, Shannon</au><au>Markowitz, Lauri E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human papillomavirus vaccination in commercially-insured vaccine-eligible males and females, United States, 2007–2014</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2018-05-31</date><risdate>2018</risdate><volume>36</volume><issue>23</issue><spage>3381</spage><epage>3386</epage><pages>3381-3386</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>In the United States, the Advisory Committee on Immunization Practices (ACIP) has recommended routine human papillomavirus (HPV) vaccination at age 11–12 years since 2006 for girls and since 2011 for boys. ACIP also recommends vaccination through age 26 for females and through age 21 for males; males may be vaccinated through age 26. We describe vaccine uptake in adolescents and young adults using data from MarketScan Commercial Claims and Encounters.
We analyzed data on persons aged 11–26 years on December 31, 2014 who were continuously enrolled in a MarketScan health plan from age 11 through year 2014, or from 2006 to 2014 if aged ≥11 years in 2006 (916,513 females, 951,082 males). Individuals were grouped based on their age (years) in 2014: 11–12 (born 2002–03), 13–14 (2000–01), 15–16 (1998–99), 17–18 (1996–97), 19–21 (1993–95), and 22–26 (1988–1992). We calculated cumulative coverage with ≥1 HPV vaccine dose by sex, birth cohort, and calendar year.
In females, the proportion initiating vaccination at age 11–12 years was low in 2008 and 2010 (12.6% and 11.1%) and higher in 2012 (15.7%) and 2014 (19.5%); in males, initiation at age 11–12 was 0.9% in 2010, 8.3% in 2012, and 15.1% in 2014. In females who aged into vaccine eligibility, cumulative coverage by 2014 was higher in older cohorts (17–18: 53%; 15–16: 47%; 13–14: 39%; 11–12: 19.5%). For males, cumulative coverage by 2014 was similar in those aged 13–14, 15–16, and 17–18 years (28.9%, 32.5%, 30.3%), and lower in those aged 11–12 (15.1%), 19–21 (18.4%), and 22–26 years (4.5%).
The proportion of males and females initiating vaccination at the recommended ages was low. Although more females than males were vaccinated in all cohorts, the male–female differences were smaller in younger than older cohorts. The trajectory of male vaccination uptake could signal higher acceptability in males.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>29735321</pmid><doi>10.1016/j.vaccine.2018.03.045</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0264-410X |
ispartof | Vaccine, 2018-05, Vol.36 (23), p.3381-3386 |
issn | 0264-410X 1873-2518 |
language | eng |
recordid | cdi_proquest_miscellaneous_2036201458 |
source | Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
subjects | Adolescents Adults Age Data processing Enrollments Epidemiology Females Girls Human papillomavirus Immunization Insurance claims Insurance claims data Insurance coverage Males Sex differences Teenagers Vaccination Vaccination policy Vaccine Vaccines Young adults |
title | Human papillomavirus vaccination in commercially-insured vaccine-eligible males and females, United States, 2007–2014 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-09T15%3A13%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20papillomavirus%20vaccination%20in%20commercially-insured%20vaccine-eligible%20males%20and%20females,%20United%20States,%202007%E2%80%932014&rft.jtitle=Vaccine&rft.au=Gargano,%20Julia%20W.&rft.date=2018-05-31&rft.volume=36&rft.issue=23&rft.spage=3381&rft.epage=3386&rft.pages=3381-3386&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2018.03.045&rft_dat=%3Cproquest_cross%3E2039813012%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2039813012&rft_id=info:pmid/29735321&rft_els_id=S0264410X18303906&rfr_iscdi=true |